Company Overview and News
June 20 (Reuters) - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
FOX BT.A LLOY JSAIY BTGOF LYG BT LLPH LLPK LLPJ LLPE JSNSF LLOBF LLPD LLPG LLDTF LLD5 LLD7 LLPC LLD6 LLD1 FOXA LLD2
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
BT.A SVTRF BTGOF STRNY TLTZY SVT BT TLTZF
MILAN, June 8 — European shares fell today as worries over global trade and an economic slowdown in the region weighed ahead of a European Central Bank meeting next week that could signal plans to wind down a massive monetary stimulus.
BT.A BTGOF BT
U.K.’s blue-chip stocks slumped Friday in a broader selloff across European equities, with investors preparing for what’s likely to be a tense gathering of leaders in the Group of Seven advanced economies in Quebec.
BT.A HRGLY LLOY BTGOF LYG BT HL LLPH LLPK LLPJ LLPE LLPD LLOBF LLPG HRGLF LLDTF LLD5 LLD7 LLPC LLD6 LLD1 LLD2
June 8 (Reuters) - Britain’s FTSE 100 index is seen opening 24 points lower at 7,680 on Friday, according to financial bookmakers, with futures up 0.67 percent ahead of the cash market open.
BP ENB LLOBF EBBNF BT.A ENBBF LLOY BTGOF LYG BP.A BP.B BT ENB LLPH LLPK BP LLPJ LLPE LLPD LLPG LLDTF LLD5 LLD7 LLPC BPAQF LLD6 LLD1 LLD2
Amazon.com Inc. (AMZN) secured rights to broadcast live Premier League soccer matches in the U.K. for the first time starting from the 2019-2020 season, as BT Group PLC (BT.A.LN) secured rights to a further 20 matches a season.
BT.A VOD VOD GLNG BTGOF CKHUY GBT BT BOLD CBB VODPF CKHUF WIFI MDCA CBB.PRB AQMS MAA
12h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
13h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...